Compare LTRN & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LTRN | ATRA |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.7M | 37.6M |
| IPO Year | 2020 | 2014 |
| Metric | LTRN | ATRA |
|---|---|---|
| Price | $2.56 | $4.18 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $25.00 | $6.00 |
| AVG Volume (30 Days) | 46.6K | ★ 111.3K |
| Earning Date | 01-01-0001 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.93 |
| Revenue | N/A | ★ $128,940,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.39 |
| Revenue Growth | N/A | ★ 1404.02 |
| 52 Week Low | $2.45 | $3.92 |
| 52 Week High | $5.74 | $19.15 |
| Indicator | LTRN | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 35.45 | 26.74 |
| Support Level | $2.53 | N/A |
| Resistance Level | $3.65 | $5.71 |
| Average True Range (ATR) | 0.20 | 0.30 |
| MACD | -0.01 | 0.28 |
| Stochastic Oscillator | 19.23 | 8.73 |
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).